ATC Group: J05AR03 Tenofovir disoproxil and emtricitabine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J05AR03 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J05 Antivirals for systemic use
3 J05A Direct acting antivirals
4 J05AR Antivirals for treatment of HIV infections, combinations
5 J05AR03 Tenofovir disoproxil and emtricitabine

Active ingredients in J05AR03

Active Ingredient Description
Tenofovir disoproxil and Emtricitabine

Emtricitabine is a nucleoside analogue of cytidine. Tenofovir disoproxil is converted in vivo to tenofovir, a nucleoside monophosphate (nucleotide) analogue of adenosine monophosphate. Both emtricitabine and tenofovir have activity that is specific to human immunodeficiency virus (HIV-1 and HIV-2) and hepatitis B virus.

Related product monographs

Title Information Source Document Type  
EMTROC Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
TRUVADA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Brazil (BR)

Canada (CA)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.